Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study reporting safety, tolerability, and pharmacokinetics of DHES0815A in HER2-positive breast cancer, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DHES0815A

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-08-05